Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

Inclusion Criteria: 1. Male or female hospitalized patients, age ≥ 18 years. 2. Patients who have developed AKI (defined by an increase in serum creatinine by ≥0.3 mg/dL within 48 hours; or an increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior seven days). 3. Adequate hematological and liver function, as assessed by the following laboratory requirements: 1. Hemoglobin ≥10.0 g/dL 2. Absolute neutrophil count (ANC) ≥1,500/mm3 3. Platelet count 100,000/mm3 4. Total bilirubin ≤1.5 x upper limit of normal (ULN). 5. ALT and AST ≤2.5 x ULN. 4. Able to provide written informed consent in compliance with the Human Investigation Review Committee (IRB). Exclusion Criteria: 1. Exposure to any investigational agent within 30 days prior to enrollment. 2. Known allergy to any of the study drugs or their excipients. 3. Currently pregnant (confirmed with a positive serum pregnancy test) or nursing. 4. Unstable or clinically significant concurrent medical condition, psychiatric illness or social situation that would, in the opinion of the investigator, jeopardize the safety of a subject and/or their compliance with the protocol. 5. Baseline CKD stage 4-5 (eGFR\<30 mL/minute/1.73 m2 as determined using the Modification of Diet in Renal Disease (MDRD) equation; in cases where the MDRD equation may not be suitable, a 24 hour urine creatinine clearance test may be substituted), prior to current hospitalization 6. Any malignancy with the exception of cervical carcinoma in situ,nonmelanoma skin cancer, or superficial bladder tumors that have been successfully and curatively treated with no evidence of recurrent or residual disease.